vs
Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and ESSENTIAL PROPERTIES REALTY TRUST, INC. (EPRT). Click either name above to swap in a different company.
ESSENTIAL PROPERTIES REALTY TRUST, INC. is the larger business by last-quarter revenue ($158.8M vs $156.4M, roughly 1.0× BIOCRYST PHARMACEUTICALS INC). On growth, ESSENTIAL PROPERTIES REALTY TRUST, INC. posted the faster year-over-year revenue change (22.8% vs 7.5%). Over the past eight quarters, ESSENTIAL PROPERTIES REALTY TRUST, INC.'s revenue compounded faster (20.6% CAGR vs 19.6%).
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
Essential Properties Realty Trust is a publicly traded real estate investment trust (REIT) that acquires, owns and manages a diversified portfolio of single-tenant net-leased commercial properties across the United States. Its assets primarily cover essential service-oriented sectors including casual dining, automotive services, medical clinics, early childhood education centers and light industrial facilities, with tenants mostly holding robust long-term operating track records.
BCRX vs EPRT — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $156.4M | $158.8M |
| Net Profit | — | $60.0M |
| Gross Margin | — | — |
| Operating Margin | 13.6% | 56.5% |
| Net Margin | — | 37.8% |
| Revenue YoY | 7.5% | 22.8% |
| Net Profit YoY | — | 6.5% |
| EPS (diluted) | $0.00 | $0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $156.4M | $158.8M | ||
| Q4 25 | $406.6M | $149.9M | ||
| Q3 25 | $159.4M | $144.9M | ||
| Q2 25 | $163.4M | $137.1M | ||
| Q1 25 | $145.5M | $129.4M | ||
| Q4 24 | $131.5M | $119.7M | ||
| Q3 24 | $117.1M | $117.1M | ||
| Q2 24 | $109.3M | $109.3M |
| Q1 26 | — | $60.0M | ||
| Q4 25 | $245.8M | $68.1M | ||
| Q3 25 | $12.9M | $65.6M | ||
| Q2 25 | $5.1M | $63.2M | ||
| Q1 25 | $32.0K | $56.1M | ||
| Q4 24 | $-26.8M | $55.4M | ||
| Q3 24 | $-14.0M | $49.1M | ||
| Q2 24 | $-12.7M | $51.5M |
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | — | ||
| Q3 25 | 98.6% | — | ||
| Q2 25 | 98.3% | — | ||
| Q1 25 | 96.9% | — | ||
| Q4 24 | 95.4% | — | ||
| Q3 24 | 97.3% | — | ||
| Q2 24 | 98.4% | — |
| Q1 26 | 13.6% | 56.5% | ||
| Q4 25 | 64.0% | 65.9% | ||
| Q3 25 | 18.6% | 64.7% | ||
| Q2 25 | 18.2% | 64.1% | ||
| Q1 25 | 14.6% | 61.6% | ||
| Q4 24 | -3.4% | 66.1% | ||
| Q3 24 | 6.6% | 59.7% | ||
| Q2 24 | 8.0% | 61.1% |
| Q1 26 | — | 37.8% | ||
| Q4 25 | 60.5% | 45.4% | ||
| Q3 25 | 8.1% | 45.3% | ||
| Q2 25 | 3.1% | 46.1% | ||
| Q1 25 | 0.0% | 43.4% | ||
| Q4 24 | -20.4% | 46.3% | ||
| Q3 24 | -12.0% | 42.0% | ||
| Q2 24 | -11.6% | 47.1% |
| Q1 26 | $0.00 | $0.28 | ||
| Q4 25 | $1.13 | $0.34 | ||
| Q3 25 | $0.06 | $0.33 | ||
| Q2 25 | $0.02 | $0.32 | ||
| Q1 25 | $0.00 | $0.29 | ||
| Q4 24 | $-0.13 | $0.31 | ||
| Q3 24 | $-0.07 | $0.27 | ||
| Q2 24 | $-0.06 | $0.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $259.0M | $15.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $4.4B |
| Total Assets | $465.1M | $7.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $259.0M | $15.2M | ||
| Q4 25 | $274.7M | $60.2M | ||
| Q3 25 | $212.9M | $23.8M | ||
| Q2 25 | $260.0M | $20.8M | ||
| Q1 25 | $295.1M | $47.0M | ||
| Q4 24 | $320.9M | $40.7M | ||
| Q3 24 | $96.8M | $32.7M | ||
| Q2 24 | $78.4M | $23.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $1.9B |
| Q1 26 | — | $4.4B | ||
| Q4 25 | $-119.2M | $4.2B | ||
| Q3 25 | $-387.9M | $3.8B | ||
| Q2 25 | $-421.6M | $3.8B | ||
| Q1 25 | $-451.9M | $3.8B | ||
| Q4 24 | $-475.9M | $3.6B | ||
| Q3 24 | $-468.6M | $3.2B | ||
| Q2 24 | $-475.6M | $3.2B |
| Q1 26 | $465.1M | $7.2B | ||
| Q4 25 | $514.2M | $6.9B | ||
| Q3 25 | $446.4M | $6.6B | ||
| Q2 25 | $457.2M | $6.3B | ||
| Q1 25 | $480.0M | $6.1B | ||
| Q4 24 | $490.4M | $5.8B | ||
| Q3 24 | $491.3M | $5.5B | ||
| Q2 24 | $472.4M | $5.3B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.69× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.56× | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | 0.69× | ||
| Q2 24 | — | 0.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
EPRT
| Rental revenue 1,2 | $149.4M | 94% |
| Other | $8.6M | 5% |
| Other revenue | $779.0K | 0% |
